Frequency of Sexual Dysfunction in Patients Treated with Desvenlafaxine: A Prospective Naturalistic Study

[EN] Despite being clinically underestimated, sexual dysfunction (SD) is one of the most frequent and lasting adverse effects associated with antidepressants. Desvenlafaxine is an antidepressant (AD) with noradrenergic and serotonergic action that can cause a lower SD than other serotonergic ADs alt...

Descripción completa

Detalles Bibliográficos
Autores: Montejo González, Ángel Luis, Becker, Joemir, Bueno Carrera, Gloria María, Fernández Ovejero, Raquel, Gallego, María T., González García, Nerea, Juanes, Adrián, Montejo, Laura, Pérez Urdániz, Antonio, Prieto, Nieves, Blanco Villegas, María José
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Universidad de Salamanca (USAL)
Repositorio:GREDOS. Repositorio Institucional de la Universidad de Salamanca
OAI Identifier:oai:gredos.usal.es:10366/146098
Acceso en línea:http://hdl.handle.net/10366/146098
Access Level:acceso abierto
Palabra clave:Switching strategy
Prsexdq-salsex questionnaire
Treatment
Antidepressant
Sexual dysfunction
Desvenlafaxine
Sexual Dysfunctions, Psychological
3211 Psiquiatría
disfunciones sexuales psicológicas
Descripción
Sumario:[EN] Despite being clinically underestimated, sexual dysfunction (SD) is one of the most frequent and lasting adverse effects associated with antidepressants. Desvenlafaxine is an antidepressant (AD) with noradrenergic and serotonergic action that can cause a lower SD than other serotonergic ADs although there are still few studies on this subject. Objective: To check the frequency of SD in two groups of depressive patients: one group was desvenlafaxine-naïve; the other was made up of patients switched to desvenlafaxine from another AD due to iatrogenic sexual dysfunction. A naturalistic, multicenter, and prospective study of patients receiving desvenlafaxine (50–100 mg/day) was carried out on 72 patients who met the inclusion criteria (>18 years old and sexually active), who had received desvenlafaxine for the first time (n = 27) or had switched to desvenlafaxine due to SD with another AD (n = 45).